How CAR-NK Cells Could Work Better than CAR-T Cells
James Crowley, Professor of Medicine emeritus at Brown University, posted on LinkedIn:
”The major hurdle addressed is donor cell rejection by the recipient’s immune system, which the authors determined is primarily mediated by host CD8+ T cells.
To overcome rejection, the researchers engineered a single gene construct that combines a selective shRNA to knock down rejection-related HLA Class I molecules, a Chimeric Antigen Receptor (CAR) for tumor targeting, and the expression of immune checkpoint ligands like PD-L1 or single-chain HLA-E (SCE).
This integrated approach not only enabled the CAR-NK cells to evade host-mediated rejection in mouse models but also surprisingly enhanced their anti-tumor activity and provided a favorable safety profile by reducing inflammatory cytokines.”
Stay updated with Hemostasis Today.
-
Feb 19, 2026, 15:16Irina Pahlevanyan: Global Leaders on Courage, Trust, and the True Purpose of Fundraising
-
Feb 19, 2026, 15:12Stéphanie Forté: Transition Readiness in Youth With Sickle Cell Disease
-
Feb 19, 2026, 15:08Tagreed Alkaltham: Strengthening Blood Inventory Governance Through RFID Technology
-
Feb 19, 2026, 14:59Başak Taburoğlu Yılmaz: Improving Diagnosis and Care for Women With Bleeding Disorders
-
Feb 19, 2026, 14:59Munira Borhany: Moving Beyond Stereotypes in the Diagnosis of Bleeding Disorders
-
Feb 19, 2026, 14:56Flora Peyvandi: Personalized VWF Dosing Revolutionizes Surgery in VWD
-
Feb 19, 2026, 14:54Michela Mazzon: The Molecular Trigger Behind the COVID19 Vaccines-Associated ITT
-
Feb 19, 2026, 14:42Luca Palombi: Real-Time Assessment of Venous Hemodynamics During Movement With DUS
-
Feb 19, 2026, 14:41Cansu Kose: Cardiovascular Disease in Women Requires More Than Male-Derived Frameworks